BR112022000251A2 - Derivados macrocíclicos de espirociclo como inibidores de mcl-1 - Google Patents

Derivados macrocíclicos de espirociclo como inibidores de mcl-1

Info

Publication number
BR112022000251A2
BR112022000251A2 BR112022000251A BR112022000251A BR112022000251A2 BR 112022000251 A2 BR112022000251 A2 BR 112022000251A2 BR 112022000251 A BR112022000251 A BR 112022000251A BR 112022000251 A BR112022000251 A BR 112022000251A BR 112022000251 A2 BR112022000251 A2 BR 112022000251A2
Authority
BR
Brazil
Prior art keywords
mcl
inhibitors
spirocycle
macrocyclic
derivatives
Prior art date
Application number
BR112022000251A
Other languages
English (en)
Inventor
Jan Rita Rombouts Frederik
Stanislas Marcella Diels Gaston
Dominique Jouffroy Matthieu
Michel Surkyn
Soufyan Jerhaoui
Emiel Maria Van Roosbroeck Yves
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112022000251A2 publication Critical patent/BR112022000251A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

derivados macrocíclicos de espirociclo como inibidores de mcl-1. a presente invenção refere-se a agentes farmacêuticos de fórmula (i) úteis para terapia e/ou profilaxia em um indivíduo, composição farmacêutica compreendendo tais compostos e ao seu uso como inibidores da mcl-1, úteis para tratar doenças como o câncer.
BR112022000251A 2019-07-09 2020-07-07 Derivados macrocíclicos de espirociclo como inibidores de mcl-1 BR112022000251A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19185177 2019-07-09
EP19218032 2019-12-19
PCT/EP2020/069097 WO2021005043A1 (en) 2019-07-09 2020-07-07 Macrocyclic spirocycle derivatives as mcl-1 inhibitors

Publications (1)

Publication Number Publication Date
BR112022000251A2 true BR112022000251A2 (pt) 2022-05-17

Family

ID=71579568

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000251A BR112022000251A2 (pt) 2019-07-09 2020-07-07 Derivados macrocíclicos de espirociclo como inibidores de mcl-1

Country Status (10)

Country Link
US (1) US20240067660A1 (pt)
EP (1) EP3997097B1 (pt)
JP (1) JP2022540825A (pt)
KR (1) KR20220034136A (pt)
CN (1) CN114096546A (pt)
AU (1) AU2020309745A1 (pt)
BR (1) BR112022000251A2 (pt)
CA (1) CA3144558A1 (pt)
MX (1) MX2022000390A (pt)
WO (1) WO2021005043A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
AU2020391106B2 (en) 2019-11-26 2024-03-21 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
AU2021381769A1 (en) * 2020-11-19 2023-06-22 Gilead Sciences, Inc. Processes and intermediates for preparing macrocyclic mcl1 inhibitors
MX2023007297A (es) * 2020-12-17 2023-07-04 Janssen Pharmaceutica Nv 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1.
WO2023088894A1 (en) * 2021-11-16 2023-05-25 Janssen Pharmaceutica Nv Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
WO2017147410A1 (en) 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
CN109071566B (zh) 2016-04-22 2021-08-31 阿斯利康(瑞典)有限公司 用于治疗癌症的大环mcl-1抑制剂
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
TWI781996B (zh) 2017-03-31 2022-11-01 瑞典商阿斯特捷利康公司 合成ｍｃｌ-１抑制劑之方法
TW201904976A (zh) 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Ｍｃｌ-１抑制劑及其使用方法
WO2019036575A1 (en) 2017-08-18 2019-02-21 Amgen Inc. MCL-1 PROTEIN INHIBITING COMPOUNDS
EP3676270A1 (en) 2017-08-29 2020-07-08 Amgen Inc. Macrocyclic compounds that inhibit mcl-1 protein
HUE057852T2 (hu) 2018-05-14 2022-06-28 Gilead Sciences Inc MCL-1 inhibítorok
AU2019374907A1 (en) 2018-11-09 2021-06-03 Prelude Therapeutics, Incorporated Spiro-sulfonamide derivatives as inhibitors of Myeloid Cell Leukemia-1 (Mcl-1) protein

Also Published As

Publication number Publication date
KR20220034136A (ko) 2022-03-17
JP2022540825A (ja) 2022-09-20
MX2022000390A (es) 2022-02-10
CA3144558A1 (en) 2021-01-14
AU2020309745A1 (en) 2022-03-03
EP3997097B1 (en) 2024-03-20
WO2021005043A1 (en) 2021-01-14
US20240067660A1 (en) 2024-02-29
EP3997097A1 (en) 2022-05-18
CN114096546A (zh) 2022-02-25

Similar Documents

Publication Publication Date Title
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
CO2021008895A2 (es) Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2a
BR112023000212A2 (pt) Éter macrocíclico contendo derivados de indol como inibidores de mcl-1
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112018074395A2 (pt) derivados de pirazol como inibidores de calicreína plasmática
BR112021025732A2 (pt) Inibidores macrocíclicos de mcl-1
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112013026834A2 (pt) composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio
BR112022025117A2 (pt) 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1
BR112019004691A2 (pt) inibidores bicíclicos em espiro da interação menina-mll
BR112018003827A2 (pt) composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição.
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
BR112019007763A2 (pt) composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112016005317A2 (pt) derivados de quinazolina e seu uso como inibidores de dna metiltransferase
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
BR112022009142A2 (pt) Derivados de indol macrocíclicos como inibidores de mcl-1